Successful rapid desensitization for cetuximab-induced anaphylaxis
Allergy, Asthma & Respiratory Disease
; : 294-296, 2015.
Article
ي Ko
| WPRIM
| ID: wpr-83768
المكتبة المسؤولة:
WPRO
ABSTRACT
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal and head/neck cancer, but can cause fatal hypersensitivity reactions in some patients. A 66-year-old male with metastatic sigmoid cancer had cetuximab-induced anaphylaxis when the first dose of cetuximab was administered. Cetuximab was safely readministered for another 15 cycles based on the rapid desensitization protocol. We experienced a case of cetuximab-induced anaphylaxis on the first exposure which was successfully managed by rapid desensitization.
Key words
النص الكامل:
1
الفهرس:
WPRIM
الموضوع الرئيسي:
Sigmoid Neoplasms
/
United States Food and Drug Administration
/
Immunoglobulins
/
Desensitization, Immunologic
/
Cetuximab
/
Hypersensitivity
/
Anaphylaxis
نوع الدراسة:
Guideline
المحددات:
Aged
/
Humans
/
Male
اللغة:
Ko
مجلة:
Allergy, Asthma & Respiratory Disease
السنة:
2015
نوع:
Article